{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal AdMSC",
            "NStudiesAvail": 430108,
            "NStudiesFound": 57,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 57,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [
                              "ADMSP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs\uff08adipose-derived multipotent mesenchymal stem cells \uff09 intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4\uff0cweek 8 with a duration for treatment for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03265613"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs\uff08adipose-derived multipotent mesenchymal stem cells \uff09 intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Calcipotriol ointment",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs plus Calcipotriol ointment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03392311"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "HB-adMSCs are autologous, adipose-derived mesenchymal stem cells. Four intravenous infusions will be administered on weeks 0, 2, 6, and 8 at a dose of 2 x 10^8 total HB-adMSC cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04228666"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in group A will receive two autologous AD-MSC administrations on day 0 and day 90 \u00b1 7",
                              "Patients in group B will receive two autologous AD-MSC administrations on day 180 \u00b1 14 and day 270 \u00b1 14"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency",
                              "Biological: Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs infusions, then Placebo",
                              "Placebo, then AD-MSCs infusions"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05329662"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [
                              "BPI+MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient will receive nerve transfer procedure without augmentation",
                              "Following nerve transfer procedure, the end-to-end anastomosis will be wrapped with HAM-AdMSC composite as augmentation"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Nerve transfer procedure",
                              "Procedure: Nerve transfer with HAM-AdMSC composite wrapping"
                        ],
                        "ArmGroupLabel": [
                              "Control group (Nerve transfer procedure)",
                              "Experimental group (Nerve transfer with HAM-AdMSC composite wrapping)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04654286"
                        ]
                  },
                  {
                        "Rank": 6,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose derived, autologous mesenchymal stem cells (AD-MSCs) at a dose of 15 million or 30 million cells will be administered via intra-arterial delivery with interventional radiology to the inferior mesenteric artery in subjects with medically refractory ulcerative colitis."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose derived, autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04312113"
                        ]
                  },
                  {
                        "Rank": 7,
                        "Acronym": [
                              "MSCSHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients",
                              "Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: adipose-derived mesenchymal stem cells",
                              "Combination Product: adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell Administration for female patients",
                              "Stem cell Administration for male patients"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03346967"
                        ]
                  },
                  {
                        "Rank": 8,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2\u00d710 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.\n\nPSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs.",
                              "Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2\u00d710 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.\n\nGu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: PSORI-CM01 formula",
                              "Biological: adipose-derived multipotent mesenchymal stem cells",
                              "Drug: Gu Ben Hua Yu formula",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "PSORI-CM01 group",
                              "Gu Ben Hua Yu group"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04785027"
                        ]
                  },
                  {
                        "Rank": 9,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Five IV infusions of autologous, adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety lab follow ups at weeks 6, 14, 26; inflammatory marker follow ups at weeks 6, 14, 26; SF-36 and PHQ-9 Questionnaires at weeks 2,6,10, 14, 18, 22, 26."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04349631"
                        ]
                  },
                  {
                        "Rank": 10,
                        "Acronym": [
                              "HB-adMSCs"
                        ],
                        "AgreementOtherDetails": [
                              "In the protocol signature page, the investigator agreed to the following: \"I further agree to treat the results of this Study as confidential information and will not submit the results of the Study for publication without prior written authorization from Hope Biosciences. \""
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Single IV administration of autologous adipose-derived mesenchymal stem cells Baseline laboratory data will be collected prior to infusion; follow up data will be compared against baseline at 1, 3, 6 and 12 months. Joint Assessment 68 will be administered at 1, 3, 6 and 12 months."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03691909"
                        ]
                  },
                  {
                        "Rank": 11,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04087889"
                        ]
                  },
                  {
                        "Rank": 12,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks.\n\nThe basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Calcipotriol ointment",
                              "Drug: PSORI-CM01 Granule",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04275024"
                        ]
                  },
                  {
                        "Rank": 13,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants with moderate to severe acute respiratory distress syndrome (6 patients)",
                              "Participants with moderate to severe acute respiratory distress syndrome (10 patients)",
                              "Participants with moderate to severe acute respiratory distress syndrome (10 patients)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: HCR040 (Phase 1)",
                              "Drug: Placebo (Phase 2)",
                              "Drug: HCR040 (Phase 2)"
                        ],
                        "ArmGroupLabel": [
                              "HCR040 (Phase 1)",
                              "Control group (Phase 2)",
                              "HCR040 (Phase 2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04289194"
                        ]
                  },
                  {
                        "Rank": 14,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with ultra filtration failure (UFF) underwent AD-MSC injection.",
                              "The patients with ultra filtration failure (UFF) underwent Placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection",
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02801890"
                        ]
                  },
                  {
                        "Rank": 15,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)",
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)",
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intra-articular injection of ADMSC",
                              "Biological: Intra-articular injection of ADMSC",
                              "Biological: Intra-articular injection of ADMSC"
                        ],
                        "ArmGroupLabel": [
                              "osteoarthritis of the knee",
                              "osteoarthritis of the hip",
                              "osteoarthritis of the glenohumeral joint"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03869229"
                        ]
                  },
                  {
                        "Rank": 16,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AstroStem-V which consists of three syringes and each syringe contains 1.0 x 10^8 cells / 3mL of saline with 30% human serum"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: AstroStem-V"
                        ],
                        "ArmGroupLabel": [
                              "AstroStem-V"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04527224"
                        ]
                  },
                  {
                        "Rank": 17,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AdMSC: Autologous adipose tissue-derived mesenchymal stem cell. Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured.",
                              "Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ARM 1: AdMSC: adipose stem cells",
                              "Other: ARM 2: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "ARM 1: AdMSC: adipose stem cells",
                              "ARM 2 Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02107118"
                        ]
                  },
                  {
                        "Rank": 18,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 200 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.",
                              "Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 100 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.",
                              "Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 50 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.",
                              "Subjects assigned to this arm will receive 5 intravenous infusions of placebo intervention (saline). Infusions will occur at weeks 0, 2, 6, 10, and 14."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs",
                              "Biological: HB-adMSCs",
                              "Biological: HB-adMSCs",
                              "Other: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic HB-adMSCs 200MM",
                              "Allogeneic HB-adMSCs 100MM",
                              "Allogeneic HB-adMSCs 50MM",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04348435"
                        ]
                  },
                  {
                        "Rank": 19,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 with the goals of ablating host repressive T cells.",
                              "Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own adipose derived mesenchymal stem cells (AD-MSCs) at a dose of 3000000/kg/d on day 1 to 3.",
                              "Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own AD-MSC transdifferentiated HSCs (AD-HSCs) at a dose of 3000000/kg/d from day 1 to 4."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Rabbit antithymoglobulin (ATG)",
                              "Drug: Rabbit antithymoglobulin (ATG)",
                              "Procedure: Adipose derived mesenchymal stem cells ( AD-MSCs)",
                              "Drug: Rabbit antithymoglobulin (ATG)",
                              "Procedure: AD-MSC transdifferentiated HSCs (AD-HSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Rabbit antithymoglobulin \uff08ATG\uff09",
                              "Rabbit ATG & AD-MSCs",
                              "Rabbit ATG & AD-HSCs"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02407470"
                        ]
                  },
                  {
                        "Rank": 20,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "HB-adMSCs will be infused three times over a six week period, spaced 14 days apart"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04063215"
                        ]
                  },
                  {
                        "Rank": 21,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Intravenousling (IV) AD-MSC in 10 patients with type 1 diabetes mellitus."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: adipose-derived messenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Adipose-derived messenchymal stem cell (AD-MSC)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05308836"
                        ]
                  },
                  {
                        "Rank": 22,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with FSGS who underwent intravenous injection of AD-MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02382874"
                        ]
                  },
                  {
                        "Rank": 23,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue (sacffold)",
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with ligament derived conditioned medium",
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition",
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition and ligament derived conditioned medium"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium",
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium",
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium",
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium"
                        ],
                        "ArmGroupLabel": [
                              "control group",
                              "conditioned medium group",
                              "stem cells group",
                              "composite group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04889963"
                        ]
                  },
                  {
                        "Rank": 24,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects assigned to this arm will receive 4 intravenous infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10.",
                              "Subjects assigned to this arm will receive 4 intravenous infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSC",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04362189"
                        ]
                  },
                  {
                        "Rank": 25,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03925649"
                        ]
                  },
                  {
                        "Rank": 26,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04029896"
                        ]
                  },
                  {
                        "Rank": 27,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)",
                              "Normal Saline with Autologous Serum"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: JointStem",
                              "Other: Placebo Control"
                        ],
                        "ArmGroupLabel": [
                              "JointStem",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04368806"
                        ]
                  },
                  {
                        "Rank": 28,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Each subject receives three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days\n\nOther Names: Celltex-AdMSCs Celltex-AdMSCs",
                              "The control group- receive three doses of placebo via intravenously infusion every three days."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose-derived stem cells",
                              "Biological: autologous adipose-derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Phase 2 AdMSC group",
                              "Phase 2 Placebo group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04428801"
                        ]
                  },
                  {
                        "Rank": 29,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)",
                              "No treatment (after high tibial osteotomy)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose Tissue derived MSCs",
                              "No treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03000712"
                        ]
                  },
                  {
                        "Rank": 30,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological/Vaccine: Allogeneic HB-adMSCs\n\nAllogeneic HB-adMSCs will be administered intravenously to study participants who qualify.\n\nOther Names: Allogeneic Hope Biosciences adipose derived mesenchymal stem cells.",
                              "Placebo will be administered intravenously to study participants who qualify.\n\nOther Names: Sterile Saline Solution 0.9%"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Biological/Vaccine: Allogeneic HB-adMSCs",
                              "Other: Placebo",
                              "Biological: Biological/Vaccine: Allogeneic HB-adMSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic HB-adMSCs.",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04995081"
                        ]
                  },
                  {
                        "Rank": 31,
                        "Acronym": [
                              "HBMS01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose derived Mesenchymal stem cells (Autologous)",
                              "Normal Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05116540"
                        ]
                  },
                  {
                        "Rank": 32,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Adipose Tissue derived MSCs Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "AdMSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01643681"
                        ]
                  },
                  {
                        "Rank": 33,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04604288"
                        ]
                  },
                  {
                        "Rank": 34,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with FSHD who underwent muscle derived stem cell and Adipose derived mesenchymal stem cell with intramuscular injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intramuscular injection"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell recipient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02208713"
                        ]
                  },
                  {
                        "Rank": 35,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04064957"
                        ]
                  },
                  {
                        "Rank": 36,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with POF who underwent intraovarian injection of 5 million mesenchymal stem cells.",
                              "The patients with POF who underwent intraovarian injection of 10 million mesenchymal stem cells.",
                              "The patients with POF who underwent intraovarian injection of 15 million mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)",
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)",
                              "Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)"
                        ],
                        "ArmGroupLabel": [
                              "5 million MSC",
                              "10 million MSC",
                              "15 million MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02603744"
                        ]
                  },
                  {
                        "Rank": 37,
                        "Acronym": [
                              "PD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Hope Biosciences adipose derived mesenchymal stem cells.",
                              "Sterile Saline Solution 0.9%"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs",
                              "Other: Placebo",
                              "Biological: HB-adMSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04928287"
                        ]
                  },
                  {
                        "Rank": 38,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells",
                              "Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "5\u00d710^6 AD-MSCs",
                              "20\u00d710^6 AD-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03461458"
                        ]
                  },
                  {
                        "Rank": 39,
                        "Acronym": [
                              "AdMSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Each subject receives three separate doses of 200 million allogeneic adipose-derived mesenchymal stem cells via intravenously infusion on days 0, 3, and 6 with a total of 600 million AdMSCs during 7 days in addition to their standard of care.",
                              "The control group will receive placebo infusion on day 0, 3 and 6 along with standard of care."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic adipose-derived stem cells",
                              "Biological: Allogeneic adipose-derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Study Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05017298"
                        ]
                  },
                  {
                        "Rank": 40,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Phase 1 Dose escalation : low Mid High Single administalation of ADR-001\n\nPhase 2 The recommended dose of ADR-001"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03254758"
                        ]
                  },
                  {
                        "Rank": 41,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow mesenchymal stem cells 10 cc by intra articular injection once",
                              "Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once",
                              "Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow mesenchymal stem cells",
                              "Biological: Adipose Mesenchymal stem cells",
                              "Biological: bone marrow & adipose mesenchymal stem cells injection"
                        ],
                        "ArmGroupLabel": [
                              "bone marrow mesenchymal stem cell",
                              "adipose mesenchymal stem cells",
                              "Bone marrow and Adipose mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04351932"
                        ]
                  },
                  {
                        "Rank": 42,
                        "Acronym": [
                              "HBPCOVID02"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "HB-ad MSC's allogeneic",
                              "Sterile Normal Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs (allogeneic)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05126563"
                        ]
                  },
                  {
                        "Rank": 43,
                        "Acronym": [
                              "CELLTOP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive a single dose of 100 million autologous, adipose derived mesenchymal stem cells. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous, Adipose derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Phase I"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03308565"
                        ]
                  },
                  {
                        "Rank": 44,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04711811"
                        ]
                  },
                  {
                        "Rank": 45,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04514952"
                        ]
                  },
                  {
                        "Rank": 46,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "a single-group, open, investigator-initiated clinical study\n\n: autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: autologous adipose derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "a single, open clinical trial"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02338271"
                        ]
                  },
                  {
                        "Rank": 47,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04772378"
                        ]
                  },
                  {
                        "Rank": 48,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.",
                              "Patients will be observed over six months while attending physical and occupational therapy. After six months, patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous, Adipose Derived Mesenchymal Stem Cells",
                              "Other: Best Medical Management: Occupational and Physical Therapy",
                              "Biological: Autologous, Adipose Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group 1: AD-MSC Injection",
                              "Treatment Group 2: Best Medical Management"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04520373"
                        ]
                  },
                  {
                        "Rank": 49,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.",
                              "3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.",
                              "corticosteroids i.e. Prednisolone \u226410mg/day or \u226420 mg every alternate day\nImmunosuppressants like Cyclophosphamide or Azathioprine at a dose of 2mg/kg/day not exceeding 150 mg/day\nAntioxidants like N-acetylcysteine (NAC) at a dose upto 1800 mg/day.\nPirfenidone at dose upto 1200 to 1800 mg/day"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Stromal Vascular Fraction (SVF)",
                              "Biological: Autologous Adipose Derived MSCs (ADMSCs)",
                              "Other: Control"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Stromal Vascular Fraction",
                              "Autologous Adipose Derived MSCs",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02135380"
                        ]
                  },
                  {
                        "Rank": 50,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04798066"
                        ]
                  },
                  {
                        "Rank": 51,
                        "Acronym": [
                              "MEIC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This is an uncontrolled trial, phase IIa, proof of concept. Group control has not been included.\n\nAll patients will receive one single dose of 120 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose derived allogenic mesenchymal stem cells (adAMSC)"
                        ],
                        "ArmGroupLabel": [
                              "Single Dose"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05521672"
                        ]
                  },
                  {
                        "Rank": 52,
                        "Acronym": [
                              "AdMSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Phase 2 Arm 1 - OA Knee",
                              "Phase 2 Arm 2 OA Knee",
                              "Phase 2 Arm 3 - OA Hip",
                              "Phase 2 Arm 4 - OA Hip",
                              "Phase 2 Arm 5 - OA Shoulder",
                              "Phase 2 Arm 6 - OA Shoulder"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04448106"
                        ]
                  },
                  {
                        "Rank": 53,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04825626"
                        ]
                  },
                  {
                        "Rank": 54,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04825613"
                        ]
                  },
                  {
                        "Rank": 55,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04064983"
                        ]
                  },
                  {
                        "Rank": 56,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
                              "hyaluronic acid"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: JointStem",
                              "Drug: Synvisc-One"
                        ],
                        "ArmGroupLabel": [
                              "JointStem",
                              "Synvisc-One"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02674399"
                        ]
                  },
                  {
                        "Rank": 57,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: AstroStem",
                              "Other: Placebo-Control"
                        ],
                        "ArmGroupLabel": [
                              "AstroStem",
                              "Placebo-Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03117738"
                        ]
                  }
            ]
      }
}